Evidence map›Paper›PMID 41110929›Full record

ReviewClinics in chest medicine2025

Genetic Familial Interstitial Lung Disease.

Rafael J Fernandez, Jonathan A Kropski

Abstract readReview
In one paragraph

Review in Clinics in chest medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Whole exome sequencing identified two novel mutations ofFrontiers in cell and developmental biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rafael J FernandezDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue S, T1218 MCN, Nashville, TN 37232, USA. Electronic address: https://twitter.com/rjfernandeziii.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue S, T1218 MCN, Nashville, TN 37232, USA; Department of Cell and Developmental Biology, Vanderbilt University, PMB407935 U-3218, Medical Research Building III, Nashville, TN 37240, USA; Department of Veterans Affairs Medical Center, 1311 24th Avenue S, Nashville, TN 37212, USA. Electronic address: jon.kropski@vumc.org.

Funding

Project 4: Defining the Molecular Natural History of Early and Progressive Pulmonary FibrosisP01HL172729 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Timothy S. Blackwell · 2024 to 2026
$11.2M
Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
Spatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0M
Unraveling the molecular origins of chronic parenchymal lung diseasesU01HL175444 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2024 to 2026
$2.8M
BLRD VA I01 BX006121NHLBI NIH HHS P01 HL172729NHLBI NIH HHS R01 HL145372NHLBI NIH HHS T32 HL094296NHLBI NIH HHS U01 HL175444
6 · The paper itself

Abstract

Interstitial lung diseases (ILDs) are a heterogenous group of disorders leading to progressive loss of lung function. A subset of ILD cases can be linked to specific single-gene causes. The available evidence suggests that known genetic etiologies should influence pharmacotherapy decisions for ILD patients, particularly when immunosuppression is considered. There is emerging consensus supporting screening of unaffected relatives of familial ILD patients to enhance early disease detection, while future studies exploring primary and secondary prevention of ILD in high-risk individuals offer hope of preventing the life-limited complications of these disorders.

Indexed as

Lung Diseases, InterstitialGenetic Predisposition to DiseaseHumansInterstitial lung diseasePulmonary fibrosisPulmonary surfactantTelomeres

Identifiers

PMID41110929
PMCPMC12697343

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.